In a public disclosure dated November 29 in Paris, the pharmaceutical company Sanofi disclosed that a new analysis of long-term Dengvaxia® data found differences in vaccine performance based on whether or not the vaccine subject has had prior dengue infection. According to Sanofi’s disclosure, there are many factors that can lead to severe dengue infection. […]
from InterAksyon http://ift.tt/2AryaXA
via Home
Post a Comment